N@N

Debjit Chattopadhyay Maintained (SRPT) at Strong Buy with Increased Target to $267 on, Jun 19th, 2018

^{Published on 2024-10-26 06:13:21 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $96 to $267 on, Jun 19th, 2018.

Debjit has made no other calls on SRPT in the last 4 months.

There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Hartaj Singh of "Oppenheimer" Downgraded from Buy to Hold on, Friday, May 4th, 2018
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $91 on, Friday, May 4th, 2018

These are the ratings of the 5 analyists that currently disagree with Debjit

---

• Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
• Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018
• Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $92 on, Friday, May 4th, 2018
• Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
• Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018

Contributing Sources

---